If you are wondering whether Amgen's current share price still offers value after a strong run, this article walks through ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Goldman Sachs reiterates Buy rating and $403 price target for Amgen due to strong portfolio execution and 6 key growth ...

Amgen (AMGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Amgen's weight management candidate looks very promising. The large biotech boasts a deep pipeline beyond that segment. Amgen's dividend looks great, and the stock is reasonably valued. Even so, there ...

In early January 2026, DISCO Pharmaceuticals announced it had granted Amgen exclusive global rights to develop and ...

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...

On Tuesday, Amgen (NASDAQ: AMGN) stock hit its one-year high, on continued momentum from a far better-than-expected quarterly earnings report. The immediate catalyst was a post-earnings price target ...